ANIXA BIOSCIENCES ($ANIX) is expected to release its quarterly earnings data on Monday, June 2nd after market close, per Finnhub. Analysts are expecting revenue of $0 ...
$ANIX insiders have traded $ANIX stock on the open market 9 times in the past 6 months. Of those trades, 9 have been purchases and 0 have been sales. Here’s a ...
) has been revised to $10.20 / share. This is an increase of 11.11% from the prior estimate of $9.18 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
Anixa Biosciences is a biotech specializing in immunotherapy treatments for breast and ovarian cancers. They are developing a vaccine for α-lactalbumin in triple-negative breast cancer and AMHR2 in ...
ANIX's focus on breast and ovarian cancer immunotherapies shows promise but lacks substantial data, with ongoing trials in early phases and limited results so far. Financially, ANIX's cash runway ...
Anixa Biosciences (NASDAQ:ANIX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a ...
An update from Anixa Biosciences ( (ANIX)) is now available. On March 10, 2026, Anixa Biosciences, Inc. held its 2026 annual meeting of stockholders, with 20.8 million of 33.4 million eligible common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results